AbbVie Inc. $ABBV Stock Holdings Trimmed by BDF Gestion

BDF Gestion trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV) by 11.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,503 shares of the company’s stock after selling 4,503 shares during the period. AbbVie accounts for 1.3% of BDF Gestion’s holdings, making the stock its 13th biggest position. BDF Gestion’s holdings in AbbVie were worth $9,287,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Foguth Wealth Management LLC. lifted its stake in AbbVie by 18.0% in the 3rd quarter. Foguth Wealth Management LLC. now owns 1,714 shares of the company’s stock valued at $489,000 after buying an additional 262 shares in the last quarter. Prospera Capital Management LLC purchased a new stake in AbbVie during the 3rd quarter worth approximately $362,000. Optivise Advisory Services LLC increased its stake in AbbVie by 5.2% during the 3rd quarter. Optivise Advisory Services LLC now owns 2,847 shares of the company’s stock worth $745,000 after buying an additional 141 shares in the last quarter. Narus Financial Partners LLC raised its holdings in shares of AbbVie by 24.9% during the third quarter. Narus Financial Partners LLC now owns 2,983 shares of the company’s stock valued at $780,000 after acquiring an additional 595 shares during the last quarter. Finally, Clark Wealth Partners raised its holdings in shares of AbbVie by 1.3% during the third quarter. Clark Wealth Partners now owns 4,110 shares of the company’s stock valued at $1,075,000 after acquiring an additional 54 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Down 0.5%

Shares of AbbVie stock traded down $1.50 on Monday, hitting $283.92. 1,337,542 shares of the company were exchanged, compared to its average volume of 6,387,841. The company has a 50-day moving average price of $262.74 and a 200 day moving average price of $239.41. The stock has a market capitalization of $501.63 billion, a price-to-earnings ratio of 80.21, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the firm earned $2.97 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts forecast that AbbVie Inc. will post 13.94 EPS for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is currently 195.48%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ABBV shares. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $225.00 price target (up from $203.00) on shares of AbbVie in a research note on Tuesday, June 23rd. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Cantor Fitzgerald raised their price objective on AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, October 8th. Citigroup lifted their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Finally, Leerink Partners upped their target price on shares of AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $277.18.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.